The recent TRIMCI study, conducted by different hospitals and scientific departments, indicate that treatment with triflusal in patients with amnestic mild cognitive impairment (CALP) can delay the progression of this disease to Alzheimer’s dementia. Numerous epidemiological studies point to the potentially beneficial anti-inflammatory drugs in Alzheimer’s disease.